Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is making progress in the clinical development of its lead candidate for multiple sclerosis, LUCID-MS, a therapy designed to target demyelination and protect or restore myelin integrity. The company announced that Phase 1 clinical studies in healthy volunteers demonstrated a favorable safety profile, with the therapy generally well tolerated, thereby supporting advancement into patient-focused studies.
In April 2026, Quantum BioPharma submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for LUCID-MS. This submission paves the way for a planned Phase 2 clinical trial in people living with multiple sclerosis. The company believes LUCID-MS may offer a differentiated, potentially first-in-class approach because it aims to directly address myelin loss and neurodegeneration, rather than relying solely on immune modulation. To strengthen operational support for the program, the company is planning a partnership with Allucent and engaging neurological specialists.
Multiple sclerosis is a chronic neurodegenerative disease characterized by the immune system attacking the protective myelin sheath covering nerve fibers, leading to communication problems between the brain and the rest of the body. Current treatments primarily focus on modulating the immune system to reduce attacks, but they do not directly repair or protect myelin. LUCID-MS is a patented new chemical entity that has shown in preclinical models the ability to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is focused on the research and development of LUCID-MS. The company also invented unbuzzd, an over-the-counter product, and spun out its OTC version to Unbuzzd Wellness Inc., retaining a 19.84% ownership stake and a royalty agreement of 7% of sales until $250 million is reached, after which the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations for pharmaceutical and medical uses.
The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM. For more information on the full article, visit https://ibn.fm/AUhNl.
